ZIVO Bioscience Stock Drops Below 200-Day Moving Average

The biotech company's shares fell as low as $9.00 on Tuesday.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

ZIVO Bioscience, Inc. (NASDAQ:ZIVO), a clinical-stage biotechnology company focused on developing precision live biotherapeutics, saw its stock price drop below its 200-day moving average of $11.67 during trading on Tuesday. The stock traded as low as $9.00 before closing at $9.25 with a trading volume of 1,402 shares. ZIVO has a market cap of $37 million and a price-to-earnings ratio of -1.90.

Why it matters

A stock's 200-day moving average is often seen as an important technical indicator, with a price drop below this level potentially signaling a bearish trend. ZIVO Bioscience's decline below this threshold could raise concerns among investors about the company's near-term prospects.

The details

ZIVO Bioscience is a clinical-stage biotech company focused on developing precision live biotherapeutics to prevent and treat gastrointestinal infections in both animal and human health markets. The company's pipeline includes ZB-01, an orally administered therapy for recurrent Clostridioides difficile infections in humans, and ZB-02, a feed-additive candidate aimed at reducing Salmonella colonization in poultry.

  • ZIVO Bioscience's stock price passed below its 200-day moving average of $11.67 during trading on Tuesday, March 4, 2026.

The players

ZIVO Bioscience, Inc.

A clinical-stage biotechnology company focused on developing precision live biotherapeutics to prevent and treat gastrointestinal infections in both animal and human health markets.

Got photos? Submit your photos here. ›

The takeaway

ZIVO Bioscience's stock price drop below its 200-day moving average could signal a bearish trend for the biotech company, raising concerns among investors about its near-term prospects as it continues to develop its pipeline of gastrointestinal infection treatments.